Therma Bright Major Milestone: Portfolio Company Inretio's Preva(R) Device Achieves 3rd Human Trial Success
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) announces a significant milestone achieved by its portfolio company, Inretio. The Preva® ischemic stroke clot removal device has successfully completed its third human trial, marking a major advancement in thrombectomy procedures. This innovative device offers enhanced precision and efficacy in blood clot removal, particularly effective when traditional treatments like tPA are insufficient.
The global coronary stents market is projected to reach $4.8 billion by 2029, presenting a substantial growth opportunity for Inretio and Therma Bright's investment. As Inretio progresses with the FDA 510K designation process, Therma Bright anticipates potential significant returns on its investment in this pioneering health-tech solution.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) annuncia un traguardo significativo raggiunto dalla sua azienda in portafoglio, Inretio. Il dispositivo per la rimozione dei coaguli da ictus ischemico Preva® ha completato con successo il suo terzo trial umano, segnando un importante progresso nelle procedure di trombectomia. Questo dispositivo innovativo offre una precisione e un'efficacia superiori nella rimozione dei coaguli di sangue, risultando particolarmente efficace quando i trattamenti tradizionali come il tPA non sono sufficienti.
Il mercato globale degli stent coronarici è previsto raggiungere 4,8 miliardi di dollari entro il 2029, presentando un'opportunità di crescita sostanziale per Inretio e per l'investimento di Therma Bright. Mentre Inretio avanza con il processo di designazione FDA 510K, Therma Bright si aspetta potenziali ritorni significativi dal suo investimento in questa soluzione innovativa nel settore della salute tecnologica.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) anuncia un hito significativo alcanzado por su empresa en cartera, Inretio. El dispositivo de eliminación de coágulos por accidente cerebrovascular isquémico Preva® ha completado con éxito su tercera prueba en humanos, marcando un avance importante en los procedimientos de trombectomía. Este dispositivo innovador ofrece una precisión y eficacia mejoradas en la eliminación de coágulos de sangre, siendo particularmente efectivo cuando los tratamientos tradicionales como el tPA son insuficientes.
Se proyecta que el mercado global de stents coronarios alcance 4.8 mil millones de dólares para 2029, presentando una oportunidad de crecimiento sustancial para Inretio y la inversión de Therma Bright. A medida que Inretio avanza en el proceso de designación FDA 510K, Therma Bright anticipa posibles retornos significativos de su inversión en esta solución innovadora en tecnología de salud.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)는 포트폴리오 회사 Inretio가 달성한 중요한 이정표를 발표합니다. Preva® 허혈성 뇌졸중 혈전 제거 장치가 세 번째 인간 임상 시험을 성공적으로 완료하였으며, 이는 혈전 제거 절차에서 중요한 발전을 나타냅니다. 이 혁신적인 장치는 혈전 제거시 정밀도와 효율성을 향상시킵니다, 특히 전통적인 치료법인 tPA가 효과적이지 않을 때 특히 효과적입니다.
글로벌 관상동맥 스텐트 시장은 2029년까지 48억 달러에 도달할 것으로 예상 되며, 이는 Inretio와 Therma Bright의 투자에 대한 상당한 성장 기회를 제공합니다. Inretio가 FDA 510K 지정 과정을 진행함에 따라, Therma Bright는 이 혁신적인 헬스테크 솔루션에 대한 투자에서 잠재적으로 중대한 수익을 기대하고 있습니다.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) annonce une étape importante atteinte par sa société de portefeuille, Inretio. Le dispositif d'élimination des caillots pour AVC ischémique, Preva®, a réussi à compléter son troisième essai humain, marquant un avancement majeur dans les procédures de thrombectomie. Cet appareil innovant offre une précision et une efficacité accrues dans l'élimination des caillots sanguins, particulièrement efficace lorsque les traitements traditionnels comme le tPA sont insuffisants.
Le marché mondial des stents coronaires devrait atteindre 4,8 milliards de dollars d'ici 2029, présentant une opportunité de croissance substantielle pour Inretio et l'investissement de Therma Bright. Alors qu'Inretio progresse dans le processus de désignation FDA 510K, Therma Bright anticipe des retours significatifs sur son investissement dans cette solution pionnière en technologie de santé.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) gibt einen bedeutenden Meilenstein bekannt, den das Portfolio-Unternehmen Inretio erreicht hat. Das Preva®-Gerät zur Entfernung von Blutgerinnseln bei ischämischem Schlaganfall hat erfolgreich seine dritte klinische Studie am Menschen abgeschlossen, was einen großen Fortschritt in den Thrombektomie-Verfahren markiert. Dieses innovative Gerät bietet eine verbesserte Präzision und Effizienz bei der Entfernung von Blutgerinnseln und ist insbesondere wirksam, wenn traditionelle Behandlungen wie tPA unzureichend sind.
Der globale Markt für koronare Stents wird voraussichtlich bis 2029 4,8 Milliarden US-Dollar erreichen, was eine erhebliche Wachstumschance für Inretio und die Investition von Therma Bright darstellt. Während Inretio mit dem FDA 510K-Zulassungsverfahren voranschreitet, erwartet Therma Bright potenziell signifikante Renditen aus seiner Investition in diese bahnbrechende Gesundheits-Technologielösung.
- Successful completion of third human trial for Preva® device
- Potential market opportunity in $4.8 billion global coronary stents market by 2029
- Progress towards FDA 510K designation
- None.
Game-Changing Innovation Poised to Transform Stroke and Blood Clot Treatment
Therma Bright's Strategic Investment Helps Medical Device Company Demonstrate Efficacy and Safety in Transforming Ischemic Stroke Care
Toronto, Ontario--(Newsfile Corp. - August 27, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is thrilled to announce a groundbreaking achievement by its investment portfolio company, Inretio. Inretio's Preva® ischemic stroke clot removal device has successfully completed its third (3rd) human trial, as announced by the device company via their LinkedIn page.
The Preva® device represents a significant leap forward in thrombectomy procedures, offering unparalleled precision and efficacy in blood clot removal. This cutting-edge technology is uniquely designed to safely and effectively restore blood flow in patients suffering from Ischemic strokes, even when traditional treatments, like tPA, fall short, which was noted by Dr. Gal Yaniv on his LinkedIn post around the third (3rd) patient's Preva® success. Dr. Yaniv serves as Director, Endovascular Neurosurgery unit at Sheba, Tel HaShomer City of Health, Aidoc CMO.
The unique patented solution offers a new approach to clot retrieving by reaching distally to the clot and opening the patented protective basket, as a result, potentially minimizing the risk of embolization and reducing the need for repeated maneuvers in the procedure.
Mechanical Thrombectomy is a minimally invasive procedure involving the removal of a thrombus (blood clot) from an artery in the brain. The procedure is effective for patients that won't comply with drug treatment. The result of mechanical thrombectomy will impact the patient's life and long-term disability.
As reported in a prior release, iDataResearch projects the global coronary stents market size will "reach a value of more than USD
"We are incredibly proud of Inretio's remarkable progress and the life-saving potential of its Preva® device," shared Rob Fia, CEO of Therma Bright. "This success not only underscores the transformative impact of Inretio's technology, but also highlights the strategic value of Therma Bright's investment in pioneering health-tech and med-tech solutions. As Inretio moves forward with the FDA 510K designation process, we stand ready to support their efforts in bringing this game-changing device to market."
The potential impact of Inretio's Preva® device on the global stroke and blood clot market cannot be overstated. As the demand for advanced clot removal solutions continues to grow, Therma Bright's investment in Inretio, could be positioned to yield significant returns and contribute positively to the Company's portfolio as the technology progresses and continues to yield positive human trial data. However, as with all investments, future outcomes are subject to various risks and uncertainties, and investors are encouraged to consider these factors when evaluating the overall impact on Therma Bright's financial performance.
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as human trials of Inretio's Preva® and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221218
FAQ
What is the significance of Inretio's Preva® device completing its third human trial for Therma Bright (TBRIF)?
How does the Preva® device differ from traditional stroke treatments?
What is the projected market size for coronary stents, and how might this affect Therma Bright's (TBRIF) investment in Inretio?
